FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder
Advances in Neurodevelopmental Disorders · 2023-06 · 7 (2) · 300-306
DOI: 10.1007/s41252-022-00301-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Neurodevelopmental Disorders, online erschienen am 26.10.2022. Verfasst von Mayank Gupta und 1 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gupta, M., & Gupta, N. (2023). FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder. Advances in Neurodevelopmental Disorders, 7(2), 300-306. https://doi.org/10.1007/s41252-022-00301-6
Vancouver
Gupta M, Gupta N. FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder. Advances in Neurodevelopmental Disorders. 2023;7(2):300-306. doi:10.1007/s41252-022-00301-6
BibTeX
@article{Gupta2023,
author = {Gupta, Mayank and Gupta, Nihit},
title = {FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder},
journal = {Advances in Neurodevelopmental Disorders},
year = {2023},
volume = {7},
number = {2},
pages = {300--306},
doi = {10.1007/s41252-022-00301-6}
}
EUVIMED